System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alessandro Passardi is an expert in Oncology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Alessandro Passardi in the top 1% of experts worldwide for Rectal Diseases, Intestinal Neoplasms and Gastrointestinal Neoplasms. Alessandro Passardi has authored 211 publications, the most recent in 2026, and is an investigator in 36 clinical trials, 17 of them ongoing. SLR score: 1,136 (community average: 125). How the SLR is computed.

LeadR Profile

Alessandro Passardi IRCCS Ospedale San Raffaele Italy
1 136 ScienceLeadR Reputation 1136

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Biochemistry - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 211

Citations

Citations: 3 548 1st author: 34 Last author: 21 Unique author: 0

Main journals

Ann Oncol 34
J Clin Oncol 28
Int J Mol Sci 11
Cancers (Basel) 9
Eur J Cancer 9

Best Journals

Ann Oncol 20
J Clin Oncol 14
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab as Third-Line Treatment in Circulating Tumor DNA-Selected Metastatic Colorectal Cancer (ROMANCE Trial).
PMID 42907240 — circulating tumor dna, cetuximab, trifluridine, neoplasms, bevacizumab, therapeutics, colorectal neoplasms, irinotecan		Clin Colorectal Cancer20260
Innovative pathological and therapeutic approaches for poorly cohesive gastric cancer.
PMID 42713041 — telepathology, neoplasms, carcinoma, signet ring cell, immunotherapy, therapeutics, stomach neoplasms		Front Oncol20260
Editorial: Innovative ways of targeting the RTK/RAS/RAF pathway.
PMID 42656459 — genes, ras		Front Oncol20260
Low referral uptake, not patient adherence, limits implementation of early nutritional screening in head and neck and upper gastrointestinal cancers.
PMID 42609223 — patient compliance, malnutrition, head and neck neoplasms		Front Nutr20260
Editorial: National colorectal cancer awareness month 2025: current progress and future prospects on colorectal cancer prevention, diagnosis and treatment.
PMID 42465568 — neoplasms, precision medicine, diagnosis, survivorship, therapeutics, colorectal neoplasms, artificial intelligence		Front Oncol20260

Clinical Studies 36

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 16
Phase 3 10
N/A 6
Phase 1 3
Phase 4 1

By status:

Recruiting 15
Completed 12
Active not recruiting 3
Unknown 3
Not yet recruiting 1
Suspended 1
Terminated 1

By type:

Interventional 34
Observational 2

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 6
multicentric5to9 2
multicentricup10 20

Main Topics

Ongoing Clinical Trials

17 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus
2024-519787-40-00 — stomach, esophagus, esophagogastric junction, neoplasms, adenocarcinoma, work, therapeutics, esophageal neoplasms, capecitabine, stomach neoplasms		Phase 3Not yet recruiting2026
A Randomized Active Controlled Double blind Multicenter Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First line Treatment of Metastatic Colorectal Cancer (HARMONi GI3)
2025-521587-35-00 — neoplasms, bevacizumab, response evaluation criteria in solid tumors, therapeutics, colorectal neoplasms		Phase 3Recruiting2026
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)
2023-505163-37-00 — safety, neoplasms, therapeutics, colorectal neoplasms		Phase 1Recruiting2021
CAPRI 3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected metastatic colorectal cancer patients
2024-519322-20-00 — cetuximab, neoplasms, drug therapy, therapeutics, colorectal neoplasms, chemotherapy		Phase 3Recruiting2025
Window of opportunity umbrella platform trial of short course pre operative targeted treatments in patients with molecularly selected and resectable primary colorectal cancer the UNICORN study
2022-501308-90-00 — neoplasms, therapeutics, colorectal neoplasms		Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS